Overview

Effects Dapagliflozin on Inflammatory Markers Erythropoiesis and Iron Metabolism in Patients with Type 2 Diabetes and CKD

Status:
NOT_YET_RECRUITING

Trial end date:
2027-05-01

Target enrollment:

Participant gender:

Summary

the effect of Dapagliflozin on erythropoiesis, iron metabolism and inflammatory markers in CKD with Type 2 DM-Compare between effect of placebo and dapagliflozin on erythropoiesis, iron metabolism and inflammation markers in CKD with Type 2 DM.

Phase:

PHASE3

Details

Lead Sponsor:

Assiut University

Treatments:

dapagliflozin